Christos Kyriakopoulos, MD, on Prostate Cancer: CHAARTED2 Trial Results on Cabazitaxel and Abiraterone
2024 ASCO Annual Meeting
Christos Kyriakopoulos, MD, of the University of Wisconsin Carbone Cancer Center, discusses data suggesting that adding cabazitaxel to abiraterone and prednisone improves progression-free survival in patients with metastatic castration-resistant prostate cancer who previously received chemohormonal therapy with docetaxel for hormone-sensitive disease compared with abiraterone plus prednisone alone (Abstract LBA5000).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Charter two was found positive for the primary outcome. At the time of the report of the results, there was a statistically significant difference of five months in terms of progression-free survival in favor of the patients who received cabazitaxel plus abirateron. For patients who received cabazitaxel and abirateron, the median progression-free survival was 14.9 months versus 9.9 months for the patients who received abirateron alone. So technically, the addition of cabazitaxel prolonged the progression-free survival by a little bit more than 50%.
Even though charter two was found positive for the primary outcome, it is not a practice changing study. The main reason is because the landscape, the treatment landscape for metastatic castration-sensitive disease has changed, and there are not that many patients who are currently getting docetaxel plus androgen deprivation in the castration-sensitive setting.
Nowadays, most patients receive either a double treatment, which includes treatment with abirateron or enzalutamide or any of the other second generation androgen receptor inhibitors. In cases that the patients receive treatment with docetaxel, that is usually in the context of a triplet therapy, which means that in addition to the docetaxel, they also receive treatment with abirateron or darolutamide or enzalutamide. That is the main reason that by the time these patients develop castration-resistant disease, they have already been exposed to a second generation androgen receptor inhibitor, which of course is like abirateron.
As part of charter two, we did include two correlative studies that are in progress. The first one is the analysis of circulating tumor cells for splice variant seven, and the second one that we included in charter two was disease assessment using sodium fluoride PET imaging. This is ongoing work and hopefully we will be able to present those results in the future meeting. Also, as part of the study, we did collect plasma for patients who enrolled in the study, and we hope that we will be able to secure funding for some additional studies with those samples.
The ASCO Post Staff
Fabrice Andre, MD, PhD, of Gustave Roussy and the Université Paris-Saclay, discusses a dose-expansion interim analysis of trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer (Abstract 1009).
The ASCO Post Staff
Clifford A. Hudis, MD, of the American Society of Clinical Oncology (ASCO), talks about the 2024 Annual Meeting, and a focus on the compassionate side of cancer care.
The ASCO Post Staff
Claudio Cerchione, MD, PhD, of Italy’s Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, discusses preliminary findings from a prospective trial suggesting that by adding whole-body MRI to fludeoxyglucose-18 (FDG) PET/CT scans, clinicians may detect bone lesions earlier and more accurately in patients with either newly diagnosed or relapsed multiple myeloma, thus translating into potentially better outcomes (Abstract 7512).
The ASCO Post Staff
Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, reports the results from the phase II SACI-IO trial in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who received sacituzumab govitecan-hziy with or without pembrolizumab (LBA1004).
The ASCO Post Staff
Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses 2.5-year follow-up data on epcoritamab monotherapy for patients with relapsed or refractory large B-cell lymphoma. The subcutaneous regimen continues to demonstrate durable responses (Abstract 7039).